Churg Strauss syndrome
Other Names for this Disease
- Allergic angiitis and granulomatosis
- Allergic granulomatosis
- Allergic granulomatous and angiitis
- Churg-Strauss vasculitis
Clinicopathologic Overlap Between Rare Eosinophilic Disorders: Implications for Clinical Trial Design, Wednesday, July 17, 2013
Location: Oxford, England
Description: The short-term goals of the workshop are: 1) to bring together a multidisciplinary group of clinician-scientists with expertise in rare eosinophilic disorders to discuss issues related to improved clinical trial design, including the utility of current diagnostic criteria and the validation of biomarkers of disease activity, 2) to continue fostering collaborative relationships between multidisciplinary clinical and basic science researchers interested in eosinophilic disorders, and 3) to provide a venue for establishing a formal multidisciplinary clinical subgroup of the IES. It is anticipated that the findings from this workshop will lead to improved design of multicenter clinical trials to assess the safety and efficacy of novel agents for the treatment of these disorders. Furthermore, establishing a formal clinical subgroup of IES will facilitate advocacy for new clinical trials for rare eosinophilic disorders.
8th International Eosinophil Society’s Biennial Symposium, Saturday, July 13, 2013 - Wednesday, July 17, 2013
Location: Oxford, England
Description: IES Symposium organizers’ central goal is to provide a highly interactive, interdisciplinary forum for scientific exchange and collaboration amongst junior and senior scientists in the fields of allergy, immunology, hematology, and cancer in relation to the role of the eosinophil in health and disease.
RDCRN 3rd Conference on Clinical Research for Rare Diseases, Tuesday, October 02, 2012
Location: Hilton Washington DC/Rockville Hotel & Executive Meeting Center, Rockville, MD
Description: Clinical research in rare diseases presents a number of challenges and unique issues that are not usually considered in the training of clinical investigators through existing training programs. Goals of the conference include: direct instruction of trainees and new investigators in rare disease research methodology; development of a reusable curriculum/syllabus on rare disease research methodology; and stimulation of ideas regarding the unique issues facing investigators engaged in the study of rare diseases.
VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010): Global Approach to Accessibility in Rare Diseases, Orphan Drugs and Neglected Diseases , Thursday, March 18, 2010 - Saturday, March 20, 2010
Location: Palais Rouge Convention Center, Palermo, Buenos Aires, Argentina
Description: For the first time, the VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010) was convened in the southern hemisphere in agreement with its aim of globalization of rare diseases research and orphan products development activities.
Eosinophil-Associated Disease: Approaches to Treatment , Wednesday, May 25, 2005 - Thursday, May 26, 2005
Location: University Hospital, Bern, Switzerland
Description: Idiopathic hypereosinophilic syndromes (HESs), including idiopathic HES, familial hypereosinophilia, Churg-Strauss vasculitis, and eosinophil-associated gastrointestinal disorders (EGID), are a heterogeneous group of rare disorders that are characterized by marked eosinophilia in the peripheral blood and/or tissues without identifiable cause. The goals of this conference were to bring together clinicians and scientists with expertise in the treatment of the various idiopathic hypereosinophilic disorders in order to summarize and discuss available data on efficacy and side effects of the therapeutic agents and modalities currently in use for the treatment of selected HESs, with the goal of identifying a consensus approach; to identify novel agents and/or strategies for use in future clinical trials; and to continue to expand the consortium of clinical researchers and available resources for collaborative study established at the prior workshop on the diagnosis of eosinophilic disorders in order to foster the development of multicenter protocols to study the pathogenesis and treatment of idiopathic hypereosinophilic disorders. Participants addressed the state of currently available therapies for three idiopathic HESs, taking into account recent developments in diagnostic testing, advances in the understanding of the pathogenesis of hypereosinophilic conditions, and novel strategies for the treatment of idiopathic eosinophilic disorders.
Churg-Strauss Syndrome, Thursday, September 14, 2000 - Friday, September 15, 2000
Location: NIH Campus, Bethesda, MD
Description: Churg-Strauss syndrome is a rare disease that is characterized by hypereosinophilia and vasculitis. Since the approval in 1996 of the new anti-leukotriene therapy for asthma, several new cases of Churg-Strauss syndrome have been diagnosed. It is not clear whether these cases are the result of an untoward effect of anti-leukotriene therapy or a primary eosinophilic disease that had been incorrectly diagnosed and treated as asthma. Several published reports suggest that the anti-leukotriene therapy allowed a reduction in corticosteroid therapy for asthma and thus unmasked the underlying condition of Churg-Strauss syndrome. This workshop explored the nature and magnitude of the association between anti-leukotriene therapy and Churg-Strauss syndrome and identified priorities for research into the pathogenesis of eosinophilic syndromes. Many of the scientific and therapeutic questions raised by the reports of Churg-Strauss syndrome being recognized in patients receiving anti-leukotriene therapy were addressed. The NIH workshop report on the relationship of asthma therapy and Churg-Strauss syndrome was published in the <i>Journal of Allergy and Clinical Immunology</i> in FY 2001.